TB-500 5 mg
This lot was tested by Janoshik on 19 Feb 2026. Purity was measured by RP-HPLC, 220 nm. The signed report is reproduced below; the figures on this page are transcribed from it.
- Batch number
- BK-26-0031
- Compound
- TB-500 5 mg
- Tested
- 19 Feb 2026
- Laboratory
- Janoshik
- Report reference
- Janoshik task #109773, key SYQ43F1DLHFQ
- Purity
- 99.75 % (RP-HPLC, 220 nm)
- Net peptide content
- 5.6 mg
- Purity, RP-HPLC, 220 nm
- 99.75 %
- Net peptide content
- 5.6 mg
- Tested
- 19 Feb 2026
- Laboratory
- Janoshik
What this certificate shows
Purity 99.75 %. Reversed-phase HPLC separates the contents of the vial by how they interact with the column, and a UV detector measures each peak. 99.75 % of the detected material in lot BK-26-0031 is the target peptide, TB-500 5 mg; the remaining 0.25 % is made up of closely related sequences and synthesis by-products. Purity describes what the peptide portion is, not how much powder is in the vial.
Net peptide content 5.6 mg. The amount of peptide actually present in the tested vial, as opposed to the labelled size of 5 mg. Lyophilised powder also contains counter-ions and residual moisture, so net content is the figure to use when calculating concentrations.
How each figure is measured, and the limits a lot must meet before release, are set out in our testing methods. For in-vitro laboratory research only.